Prospective Exploratory Evaluation of Cepheid Xpert Mycobacterium Tuberculosis Host Response Cartridge: A Focus on Adolescents and Young Adults

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Sep 5

PMID 39233548

Authors

Marva Seifert

Donald G Catanzaro

Michael Gracia

Naomi Hillery

Sabira Tahseen

Faisal Masood

Alamdar Hussain

Uzma Majeed

Rebecca E Coleman

Rebecca E Colman

Rehan R Syed

Antonino Catanzaro

Timothy Rodwell

Affiliations

Soon will be listed here.

Abstract

Background: An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed.

Methods: A prospective evaluation of the Cepheid GeneXpert Mycobacterium tuberculosis Host Response cartridge (Xpert-MTB-HR), a prototype blood-based host response mRNA signature assay, among individuals presenting with TB-like symptoms was performed in Pakistan and results were compared to 3 reference standards: Xpert MTB/RIF Ultra, bacteriological confirmation (Xpert MTB/RIF Ultra and/or culture positivity), and composite clinical diagnosis (clinician diagnosis, treatment initiation, Xpert MTB/RIF Ultra, and/or culture positivity). Analyses were conducted both for the entire study cohort and separately in the adolescent and young adult cohort (aged 10-24 years).

Results: A total of 497 participants, aged 6-83 years, returned valid Xpert-MTB-HR results. When a diagnostic threshold was set for a sensitivity of >90%, specificity was 32% (95% confidence interval [CI], 28%-37%) compared to Xpert MTB/RIF Ultra, 29% (95% CI, 25%-34%) compared to a bacteriological confirmation, and 22% (95% CI, 18%-26%) compared to a composite clinical diagnosis. However, when evaluating only the adolescent and young adult cohort with a diagnostic threshold set for sensitivity of >90%, specificity was 82% (95% CI, 74%-89%) compared to Xpert MTB/RIF Ultra, 84% (95% CI, 75%-90%) compared to a bacteriological confirmation, and 54% (95% CI, 44%-64%) compared to a composite clinical diagnosis.

Conclusions: While the Xpert-MTB-HR does not meet World Health Organization minimum criteria in the general population, in our study it does meet the minimum sensitivity and specificity requirements for a non-sputum-based triage test among adolescents and young adults when compared to Xpert MTB/RIF Ultra or bacteriological confirmation.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Li M, Qiu Y, Guo M, Qu R, Tian F, Wang G . Evaluation of the Cepheid 3-gene host response blood test for tuberculosis diagnosis and treatment response monitoring in a primary-level clinic in rural China. J Clin Microbiol. 2023; 61(11):e0091123. PMC: 10662368. DOI: 10.1128/jcm.00911-23. View

Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J . Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. Lancet Glob Health. 2024; 12(2):e226-e234. PMC: 11046618. DOI: 10.1016/S2214-109X(23)00541-7. View

Georgountzou A, Papadopoulos N . Postnatal Innate Immune Development: From Birth to Adulthood. Front Immunol. 2017; 8:957. PMC: 5554489. DOI: 10.3389/fimmu.2017.00957. View

Sodersten E, Ongarello S, Mantsoki A, Wyss R, Persing D, Banderby S . Diagnostic Accuracy Study of a Novel Blood-Based Assay for Identification of Tuberculosis in People Living with HIV. J Clin Microbiol. 2020; 59(3). PMC: 8106701. DOI: 10.1128/JCM.01643-20. View

Snow K, Sismanidis C, Denholm J, Sawyer S, Graham S . The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 2018; 51(2). DOI: 10.1183/13993003.02352-2017. View

Chiang S, Waterous P, Atieno V, Bernays S, Bondarenko Y, Cruz A . Caring for Adolescents and Young Adults With Tuberculosis or at Risk of Tuberculosis: Consensus Statement From an International Expert Panel. J Adolesc Health. 2023; 72(3):323-331. PMC: 10265598. DOI: 10.1016/j.jadohealth.2022.10.036. View

Simon A, Hollander G, McMichael A . Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015; 282(1821):20143085. PMC: 4707740. DOI: 10.1098/rspb.2014.3085. View

Olbrich L, Verghese V, Franckling-Smith Z, Sabi I, Ntinginya N, Mfinanga A . Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries. Lancet Infect Dis. 2023; 24(2):140-149. PMC: 10808504. DOI: 10.1016/S1473-3099(23)00491-7. View

10.

Garcia-Basteiro A, Schaaf H, Diel R, Migliori G . Adolescents and young adults: a neglected population group for tuberculosis surveillance. Eur Respir J. 2018; 51(2). DOI: 10.1183/13993003.00176-2018. View

11.

Sutherland J, Van Der Spuy G, Gindeh A, Thuong N, Namuganga A, Owolabi O . Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. Clin Infect Dis. 2021; 74(12):2136-2141. PMC: 9258935. DOI: 10.1093/cid/ciab839. View

12.

Ungprasert P, Carmona E, Utz J, Ryu J, Crowson C, Matteson E . Epidemiology of Sarcoidosis 1946-2013: A Population-Based Study. Mayo Clin Proc. 2016; 91(2):183-8. PMC: 4744129. DOI: 10.1016/j.mayocp.2015.10.024. View

13.

Laycock K, Enane L, Steenhoff A . Tuberculosis in Adolescents and Young Adults: Emerging Data on TB Transmission and Prevention among Vulnerable Young People. Trop Med Infect Dis. 2021; 6(3). PMC: 8396328. DOI: 10.3390/tropicalmed6030148. View

14.

Sawyer S, Azzopardi P, Wickremarathne D, Patton G . The age of adolescence. Lancet Child Adolesc Health. 2018; 2(3):223-228. DOI: 10.1016/S2352-4642(18)30022-1. View

15.

Vanden Driessche K, Persson A, Marais B, Fink P, Urdahl K . Immune vulnerability of infants to tuberculosis. Clin Dev Immunol. 2013; 2013:781320. PMC: 3666431. DOI: 10.1155/2013/781320. View

16.

Baughman R, Field S, Costabel U, Crystal R, Culver D, Drent M . Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc. 2016; 13(8):1244-52. DOI: 10.1513/AnnalsATS.201511-760OC. View

17.

Warsinske H, Rao A, Moreira F, Santos P, Liu A, Scott M . Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. JAMA Netw Open. 2019; 1(6):e183779. PMC: 6324428. DOI: 10.1001/jamanetworkopen.2018.3779. View

18.

Seddon J, Chiang S, Esmail H, Coussens A . The Wonder Years: What Can Primary School Children Teach Us About Immunity to ?. Front Immunol. 2019; 9:2946. PMC: 6300506. DOI: 10.3389/fimmu.2018.02946. View

19.

Snow K, Cruz A, Seddon J, Ferrand R, Chiang S, Hughes J . Adolescent tuberculosis. Lancet Child Adolesc Health. 2019; 4(1):68-79. PMC: 7291359. DOI: 10.1016/S2352-4642(19)30337-2. View

20.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View